Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors - Trial NCT05429762
Access comprehensive clinical trial information for NCT05429762 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sanofi and is currently Not yet recruiting. The study focuses on Neoplasm. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sanofi
Timeline & Enrollment
Phase 1
Sep 30, 2022
Nov 04, 2024
Primary Outcome
Change from baseline in QT-interval corrected (QTcF) centrally assessed
Summary
This is a Phase1, single-arm study for treatment. This is a prospective multicenter,
 multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT
 interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell
 lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which
 in the judgement of the Investigator, no standard alternative therapy is available.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05429762
Non-Device Trial